急重症科指南

订阅

MedSci主页 / 所有栏目 / 急重症科指南

2020 SCCM国际共识：危重症后远期损害的预测和识别

2020-11-20 美国重症医学会 Crit Care Med . 2020 Nov;48(11):1670-1679.

危重症患者

2020年11月，美国重症医学会(SCCM)发布了危重症后远期损害的预测和识别国际共识建议，专家强烈建议在出院后2~4 周内对选定的幸存者进行重症监护综合征（PICS） 问题评估，并且在重要

中文标题：

2020 SCCM国际共识：危重症后远期损害的预测和识别

英文标题：

Society of Critical Care Medicine's International Consensus Conference on Prediction and Identification of Long-Term Impairments After Critical Illness

发布机构：

美国重症医学会

发布日期：

2020-11-20

简要介绍：

2020年11月，美国重症医学会(SCCM)发布了危重症后远期损害的预测和识别国际共识建议，专家强烈建议在出院后2~4 周内对选定的幸存者进行重症监护综合征（PICS） 问题评估，并且在重要的健康和生活改变时对PICS 问题进行连续的评估。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 SCCM国际共识：危重症后远期损害的预测和识别.pdf)] GetToolGuiderByIdResponse(projectId=1, id=dd18e1c002060232, title=2020 SCCM国际共识：危重症后远期损害的预测和识别, enTitle=Society of Critical Care Medicine's International Consensus Conference on Prediction and Identification of Long-Term Impairments After Critical Illness, guiderFrom=Crit Care Med . 2020 Nov;48(11):1670-1679., authorId=0, author=, summary=2020年11月，美国重症医学会(SCCM)发布了危重症后远期损害的预测和识别国际共识建议，专家强烈建议在出院后2~4 周内对选定的幸存者进行重症监护综合征（PICS） 问题评估，并且在重要, cover=https://img.medsci.cn/2021214/1613236401858_2020535.jpg, journalId=0, articlesId=null, associationId=385, associationName=美国重症医学会, associationIntro=《美国重症医学会》，是世界上最大的重症医学会，具有多学科，多专业的特点，拥有近100多个国家的16000名成员。sccm网站集临床，科研和教学于一体，跟踪报道重症医学的最新研究成果。学术会议发布，投稿和报名。, copyright=0, guiderPublishedTime=Fri Nov 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年11月，美国重症医学会(SCCM)发布了危重症后远期损害的预测和识别国际共识建议，专家强烈建议在出院后2~4 周内对选定的幸存者进行重症监护综合征（PICS）&nbsp;问题评估，并且在重要的健康和生活改变时对PICS 问题进行连续的评估。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=14375, tagName=危重症患者)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=14375, guiderKeyword=危重症患者, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2546, appHits=94, showAppHits=0, pcHits=479, showPcHits=2452, likes=1, shares=4, comments=4, approvalStatus=1, publishedTime=Sun Feb 14 01:22:16 CST 2021, publishedTimeString=2020-11-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Feb 14 01:13:27 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:46:55 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SCCM国际共识：危重症后远期损害的预测和识别.pdf)])
2020 SCCM国际共识：危重症后远期损害的预测和识别.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1071359, encodeId=997e10e135999, content=确实随访很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8915461375, createdName=ms9000000763637162, createdTime=Thu Nov 18 11:06:14 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974734, encodeId=c2f69e473447, content=不错，希望下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Fri Jun 18 21:38:23 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960406, encodeId=a84e96040649, content=随访很重要，但不容易, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7781328397, createdName=cheng1697, createdTime=Sun Apr 25 16:33:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924510, encodeId=e56292451080, content=哈哈哈哈哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65e05268194, createdName=14818876m89暂无昵称, createdTime=Sun Feb 14 06:26:07 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-11-18 ms9000000763637162

    确实随访很重要

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1071359, encodeId=997e10e135999, content=确实随访很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8915461375, createdName=ms9000000763637162, createdTime=Thu Nov 18 11:06:14 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974734, encodeId=c2f69e473447, content=不错，希望下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Fri Jun 18 21:38:23 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960406, encodeId=a84e96040649, content=随访很重要，但不容易, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7781328397, createdName=cheng1697, createdTime=Sun Apr 25 16:33:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924510, encodeId=e56292451080, content=哈哈哈哈哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65e05268194, createdName=14818876m89暂无昵称, createdTime=Sun Feb 14 06:26:07 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-06-18 471239581

    不错，希望下载

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1071359, encodeId=997e10e135999, content=确实随访很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8915461375, createdName=ms9000000763637162, createdTime=Thu Nov 18 11:06:14 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974734, encodeId=c2f69e473447, content=不错，希望下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Fri Jun 18 21:38:23 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960406, encodeId=a84e96040649, content=随访很重要，但不容易, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7781328397, createdName=cheng1697, createdTime=Sun Apr 25 16:33:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924510, encodeId=e56292451080, content=哈哈哈哈哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65e05268194, createdName=14818876m89暂无昵称, createdTime=Sun Feb 14 06:26:07 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-04-25 cheng1697

    随访很重要，但不容易

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1071359, encodeId=997e10e135999, content=确实随访很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8915461375, createdName=ms9000000763637162, createdTime=Thu Nov 18 11:06:14 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974734, encodeId=c2f69e473447, content=不错，希望下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Fri Jun 18 21:38:23 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960406, encodeId=a84e96040649, content=随访很重要，但不容易, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7781328397, createdName=cheng1697, createdTime=Sun Apr 25 16:33:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924510, encodeId=e56292451080, content=哈哈哈哈哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65e05268194, createdName=14818876m89暂无昵称, createdTime=Sun Feb 14 06:26:07 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-02-14 14818876m89暂无昵称

    哈哈哈哈哈

    0

相关指南

中国呼吸危重症患者营养支持治疗专家共识

中国医师协会呼吸医师分会 · 2020-03-03

2020 意见书：重症患者抗菌药物治疗监测

欧洲危重病医学会(ESICM,European Society of Intensive Care Medicine) · 2020-05-07

2017 SCCM/ESICM指南：危重患者危重症相关性肾上腺皮质功能不全的管理

美国重症医学会(SCCM,Society of Critical Care Medicine) · 2017-09-21

拓展阅读

2017 SCCM/ESICM指南：危重患者危重症相关性肾上腺皮质功能不全的管理

美国重症医学会(SCCM,Society of Critical Care Medicine) · 2017-09-21

2020 意见书：重症患者抗菌药物治疗监测

欧洲危重病医学会(ESICM,European Society of Intensive Care Medicine) · 2020-05-07

中国呼吸危重症患者营养支持治疗专家共识

中国医师协会呼吸医师分会 · 2020-03-03

危重症患者腹内压监测的最佳证据总结

浙江大学医学院附属第一医院 · 2022-05-15

早期康复治疗对预防危重症患者ICU获得性衰弱的证据总结

贵州医科大学附属医院 · 2023-02-01